Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex

Isatuximab could be the next building block in Sanofi's ambitions to rebuild in oncology. The CD38-targeting antibody extended PFS in relapsed/refractory multiple myeloma in combination with Celgene's Pomalyst and dexamethasone.

Open Book Of prostate multiple myeloma, Conceptual Image - Image

Sanofi's CD38-targeting antibody isatuximab could be the company's next new cancer drug as it looks to rebuild in oncology. The pharma said Feb. 4 that it will file isatuximab with regulatory authorities in the US and Europe in the first half of 2019 based on the positive results from a Phase III trial in relapsed/refractory multiple myeloma (r/rMM).

But isatuximab, if approved, will be in a come-from-behind position following Johnson & Johnson/Genmab AS's Darzalex (daratumumab), which was approved in June 2016 as the first human anti-CD38...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip